News and Events
Subscribe to the CDI Press Releases RSS Feed

Press Releases

Subscribe to the CDI Press Releases RSS Feed

In the News

Events

Awards & Accolades

Subscribe to the CDI Press Releases RSS Feed

eNewsletter Archive

Media Library

Subscribe to CDI News Updates

MEDIA CONTACT:
Joleen Rau
Senior Director
Marketing & Communications
Cellular Dynamics International, Inc.
(608) 310-5142
Contact Media Relations

Media Library

Download illustrations, photographs, and backgrounder content. If you have further questions, please contact CDi media relations.

  Item
Summary
 Download
     


Cardiotoxicity of iCell Cardiomyocytes Measured with Multi-Glow Multiplex Cytoxicity Assay
Caption:
Viability (blue) and death (red) of iCell® Cardiomyocytes (CDI) in response to Staurosporine application measured simultaneously with MultiTox-Glo Multiplex Cytotoxicity Assay (Promega).
© Cellular Dynamics International.

hi res jpg
(441 Kb)

CDI SAB, Lab

CDI Scientific Advisory Board: George Church, James Thomson, and Leroy Hood
Caption:
Dr. George Church and Dr. Leroy Hood, pioneers in personalized medicine, join stem cell pioneer Dr. James Thomson on Cellular Dynamics' Scientific Advisory Board.
© Cellular Dynamics International.

hi res jpg
(1Mb)

CDI SAB

CDI Scientific Advisory Board: George Church, James Thomson, and Leroy Hood
Caption:
Dr. George Church and Dr. Leroy Hood, pioneers in personalized medicine, join stem cell pioneer Dr. James Thomson on Cellular Dynamics' Scientific Advisory Board.
© Cellular Dynamics International.

hi res jpg (1.1Mb)

iiPS 2.0

iPS 2.0: A Step Closer to Personalized Medicine.
Caption:
The original iPS method demonstrated that ordinary skin cells could be reprogrammed to a stem cell state through the insertion of four genes. However, because the inserted genes are not an innate part of the cell’s DNA and are integrated directly into the genome via a viral vector, concerns have arisen over the potential risks associated with the insertion of foreign DNA into the cell’s genome. The iPS 2.0TM method employs vectors that do not integrate into the genome, thus allowing for the differentiation of cells genetically identical to the original starting material and alleviating safety concerns for use of iPS cells in a clinical setting.
© Cellular Dynamics International.

hi res jpg (~1Mb, WinZip)

low res jpg (220 Kb)


Dr. Junying Yu

Dr. Junying Yu, CDI Senior Research Fellow
Caption:
Dr. Yu is one of the world's leading experts in human induced pluripotent stem (iPS) cell technology,  focusing on reprogramming adult cells to a fully pluripotent state and then differentiating them into any cell type in the body.
Photo by Bryce Richter.
© The University of Wisconsin Board of Regents.

hi res jpg (6.1Mb)
Dr. Junying Yu's Bio

Biography:
Dr. Junying Yu is one of the world's leading experts in human induced pluripotent stem (iPS) cell technology,  focusing on reprogramming adult cells to a fully pluripotent state and then differentiating them into any cell type in the body. Her breakthrough research enables the creation of stem cells from any individual, thus driving forward regenerative medicine and personalized therapeutics, as well as circumnavigates the ethical issues surrounding embryonic stem cells. Yu was lead author on the first-ever paper published on human iPS cell research in November 2007 and a second major milestone paper on vector-free human iPS cell research published in March 2009, both in the top journal Science. In 2003 she joined the UW-Madison lab of Dr. James Thomson ...

PDF (100Kb)